A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with Chemotherapy (Tumor-DNA Damaging Agent) for the Treatment of Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Etidaligide (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms DRIIV-1b
- Sponsors Onxeo SA
- 13 Nov 2019 According to an Onxeo SA media release, preliminary data from this trial is expected in few weeks.
- 18 Sep 2019 According to an Onxeo SA media release, the company has initiated the second part of this study. Initial results from the second part of the study are expected at the end of the year.
- 18 Sep 2019 Results presented in an Onxeo media release.